Same Day Versus Next Day Discharge: Ambulatory Closure Device Percutaneous Intervention (ABCD-PCI)
26 juillet 2011 mis à jour par: Icahn School of Medicine at Mount Sinai
Ambulatory Closure Device Percutaneous Intervention: a Multi-Center Randomized Trial Evaluating Patient Satisfaction, Safety, and Cost Effectiveness of Ambulatory PCI in the Current Era
This is a multi-center trial that will evaluate the safety, feasibility, and cost effectiveness of discharging patients, who have had successful percutaneous coronary intervention (PCI) and deployment of the AngiomaxTM closure device, 6 hours after against 24 hours after the procedure.
Patients will be randomized in a 3 (test): 1 (control) fashion and will have a study population of 600 patients over 6 investigational sites all within the United States.
Patients <65 years old will be chosen in order to stay within the low risk group and will be followed up after 24 hours, 7 days, and 30 days via phone or office visit.
The primary endpoint will be a composite of major adverse cardiac and cerebral events, and the incidence of major bleeding or vascular complications.
Data acquired from the study, such as blinded financial information and patient satisfaction surveys, will be used in order to evaluate cost analysis and safety of the procedure.
Aperçu de l'étude
Statut
Complété
Les conditions
Intervention / Traitement
Description détaillée
Closure devices are a relatively new method for sealing the femoral arterial puncture following procedures including percutaneous intervention (PCI).
Because the risk of severe complications (e.g., bleeding, myocardial infarction, stroke, and mortality) associated with PCI when closure devices are very low, many patients undergoing PCI may be considered eligible for a same day hospital discharge.
As the practice of ambulatory PCI is becoming more common, it is important to evaluate the readiness of patients under-going PCI for same-day discharge and anxiety and coping abilities of patients post-discharge.
Our hypothesis is that same day discharge of patients who have undergone a PCI procedure with closure using a vascular closure device is safe, patients will be comfortable with a same day discharge and this process will be more cost efficient than the current standard of staying in the hospital overnight.
The current pilot study is a multi-center, randomized parallel arm, controlled trial of low-risk patients undergoing an elective PCI procedure.
Overall, 600 patients will be enrolled.
After providing informed consent, participants will be randomized to leave the hospital on the same day as the PCI procedure or stay overnight in a 1:1 ratio.
Data collection includes a self-administered questionnaire at hospital discharge, telephone interviews at 7-days and 30-days post-hospital discharge, and chart abstraction.
The primary outcome for this study is differences across randomization arm in patient satisfaction scores on the validated 10-item Post-discharge coping difficulty scale assessed 7 days post-discharge.
Secondary outcomes will include differences across randomization group for symptoms of anxiety, readiness for hospital discharge, patient satisfaction with the timing of their discharge, post-procedure pain and soreness, and cost-savings.
While a data safety monitoring board will track all adverse events (i.e., myocardial infarction, hematoma, hospitalizations, and mortality), we anticipate too few events to occur to make meaningful inferences beyond that PCI is safe regardless of the timing of hospital discharge.
The data from this pilot study will determine the comfort patients experience after undergoing PCI with an ambulatory (i.e, same-day) hospital discharge.
Furthermore, this pilot study will provide the foundation for a large scale non-inferiority study of same-day discharge on outcomes including myocardial infarction, bleeding, and mortality.
Such data will indicate the overall feasibility of early ambulatory PCI and has the potential to radically alter health care delivery following PCI.
Type d'étude
Observationnel
Inscription (Réel)
303
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
New York
-
New York, New York, États-Unis, 10029
- Mount Sinai School of Medicine
-
-
Texas
-
Dallas, Texas, États-Unis, 75226
- Baylor University Medical Center
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
18 ans à 75 ans (Adulte, Adulte plus âgé)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Tout
Méthode d'échantillonnage
Échantillon de probabilité
Population étudiée
The target population for this study will include patients undergoing an elective PCI.
Overall, 600 patient will be recurited from two sites in the United Sates.
As this is a feasiblity study, enrollment will be restricted to low-risk patients.
For this reason, the study will be limited to patients under 75 years of age.
All patients must meet all of the inclusion criteria and have none of the exclusion criteria to be enrolled into the study.
La description
Inclusion Criteria:
. <75 years of age at the time of procedure.
2. Patient has a type A or B lesion(s)
3. Femoral access site is amenable to closure with a vascular closure device.
4. Over 2 hours since the completion of the PCI procedure (at least 2 hours must elapse from completion of the PCI before subjects become eligible).
Exclusion Criteria:
- Patient has a life expectancy less than 12 months.
- Patient has recent evidence of an acute coronary syndrome (MI)
- Femoral access is difficult or site is not amenable to closure device
- Anticoagulants other than unfractionated heparin or bivalirudin were used during the procedure (i.e. enoxaparin).
- Patient has sub optimal angiographic outcome or clinical complication(s) during PCI
- The PCI occurred in something other than a native coronary artery
- Angiographic evidence of thrombus
- Patient has more than 3 stents implanted during this PCI
- Patient has an INR >2, Platelet count <100,000 or Hematocrit <25
- Occlusion of major side branch during PCI of >1.5mm
- Patient has ejection fraction ≤30%
- Known allergy to PCI procedural medications
- Patient reports living further than 30 minutes from a hospital by ambulance.
- Patient provides informed consent and agrees to the follow-up schedule.
- Evidence of vascular complication(s) (e.g. dissection, hematoma, bleeding) peri-procedure
- Patient is pregnant
- Evidence of infection (e.g. fever, pus, swelling) peri-procedure
- Patients with chronic renal insufficiency (e.g. serum creatinine ≥1.5 mg/dL)
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: Cas-témoins
- Perspectives temporelles: Éventuel
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
overnight
Subjects that stay overnight at the hospital.
|
At six hours post-PCI,patients will be randomized to be discharged immediately or to stay overnight in the hospital for observation and discharged the following day.
Randomization will occur in a 1:1 ratio.
Additionally, randomization will be performed stratified by study site.
|
|
Next Day Discharge
Subjects that are discharged on the same day of the procedure.
|
At six hours post-PCI,patients will be randomized to be discharged immediately or to stay overnight in the hospital for observation and discharged the following day.
Randomization will occur in a 1:1 ratio.
Additionally, randomization will be performed stratified by study site.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Post-hospitalization patient satisfaction
Délai: 30 days after enrollment
|
The primary endpoint is the difference in post-hospitalization patient satisfaction during the initial seven days following PCI.
Post-hospitalization patient satisfaction will be assessed using the 10-item Post-Discharge Coping Difficulty scale.
|
30 days after enrollment
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Patient satisfaction with timing of discharge
Délai: 30 days after enrollment
|
Secondary outcomes will include post-hospital anxiety, readiness for hospital discharge, patient satisfaction with the timing of their discharge, post-procedure pain and soreness, resource utilization and cost-savings.
|
30 days after enrollment
|
|
Patient Satisfaction Outcome Assessment
Délai: 30 days After Enrollment
|
These outcomes will be assessed using standardized questionnaires and validated techniques.
The composite of major adverse cardiac events (MACE) and cerebral events and the incidence of major bleeding or vascular complications will be monitored for all patients through the 30 day follow-up period.
|
30 days After Enrollment
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Michael C Kim, MD, Icahn School of Medicine at Mount Sinai
Publications et liens utiles
La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude
1 janvier 2008
Achèvement primaire (Réel)
1 juin 2010
Achèvement de l'étude (Réel)
1 juin 2010
Dates d'inscription aux études
Première soumission
31 mars 2010
Première soumission répondant aux critères de contrôle qualité
27 octobre 2010
Première publication (Estimation)
29 octobre 2010
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
28 juillet 2011
Dernière mise à jour soumise répondant aux critères de contrôle qualité
26 juillet 2011
Dernière vérification
1 juillet 2011
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- GCO 07-1324
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .